Triple

T20301280
Position Surface form Disambiguated ID Type / Status
Subject Brilinta E505483 entity
Predicate marketedAs P1395 FINISHED
Object Brilique
Brilique is a brand name for the antiplatelet medication ticagrelor, used to reduce the risk of cardiovascular events such as heart attacks and strokes in patients with acute coronary syndromes or a history of myocardial infarction.
 E1423946 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Brilique | Statement: [Brilinta, marketedAs, Brilique]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: Brilique
Context triple: [Brilinta, marketedAs, Brilique]
  • A. Atalide
    Atalide is a central tragic heroine in Jean Racine’s 1672 play "Bajazet," caught in a complex web of love, jealousy, and political intrigue in the Ottoman court.
  • B. Docefrez
    Docefrez is a branded formulation of the chemotherapy drug docetaxel used to treat various cancers, including breast, lung, and prostate cancer.
  • C. Acomplia
    Acomplia is the brand name for rimonabant, a cannabinoid receptor antagonist that was developed as an anti-obesity drug but withdrawn due to psychiatric side effects.
  • D. Andexxa
    Andexxa is a recombinant modified human factor Xa protein used as a reversal agent to counteract the anticoagulant effects of factor Xa inhibitors such as rivaroxaban and apixaban.
  • E. Kalydeco
    Kalydeco is a prescription medication used to treat certain forms of cystic fibrosis by improving the function of defective CFTR proteins.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Brilique
Triple: [Brilinta, marketedAs, Brilique]
Generated description
Brilique is a brand name for the antiplatelet medication ticagrelor, used to reduce the risk of cardiovascular events such as heart attacks and strokes in patients with acute coronary syndromes or a history of myocardial infarction.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07 
Target entity: Brilique
Target entity description: Brilique is a brand name for the antiplatelet medication ticagrelor, used to reduce the risk of cardiovascular events such as heart attacks and strokes in patients with acute coronary syndromes or a history of myocardial infarction.
  • A. Atalide
    Atalide is a central tragic heroine in Jean Racine’s 1672 play "Bajazet," caught in a complex web of love, jealousy, and political intrigue in the Ottoman court.
  • B. Docefrez
    Docefrez is a branded formulation of the chemotherapy drug docetaxel used to treat various cancers, including breast, lung, and prostate cancer.
  • C. Acomplia
    Acomplia is the brand name for rimonabant, a cannabinoid receptor antagonist that was developed as an anti-obesity drug but withdrawn due to psychiatric side effects.
  • D. Andexxa
    Andexxa is a recombinant modified human factor Xa protein used as a reversal agent to counteract the anticoagulant effects of factor Xa inhibitors such as rivaroxaban and apixaban.
  • E. Kalydeco
    Kalydeco is a prescription medication used to treat certain forms of cystic fibrosis by improving the function of defective CFTR proteins.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69e0b4b8ab648190906e18538c250148 completed April 16, 2026, 10:06 a.m.
NER Named-entity recognition batch_69e6770c700c81909da247cef0d0f1eb completed April 20, 2026, 6:57 p.m.
NED1 Entity disambiguation (via context triple) batch_6a08611762e481909ee2f41434c86aa5 completed May 16, 2026, 12:20 p.m.
NEDg Description generation batch_6a0863506f4481909c106c49f6b71191 completed May 16, 2026, 12:30 p.m.
NED2 Entity disambiguation (via description) batch_6a0863f4bb788190b6ef1fe57279badb completed May 16, 2026, 12:32 p.m.
Created at: April 16, 2026, 11:17 a.m.